http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2367892-T3
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2004-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31bd57f6f7f91175d7daf7c14c814581 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7108f52f7bd0e4b37f5a78fe68ed8ef9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_977a6bb509bbea6fabf375dc58d226e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cc9891845fc132d9c59a05a5ef598aa |
| publicationDate | 2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2367892-T3 |
| titleOfInvention | THERAPY PROCEDURES FOR CANCERS RELATED TO CELLS B. |
| abstract | An anti-CD40 antagonist antibody or an antigen-binding fragment thereof for use in a method of treating a human subject of a cancer characterized by a neoplastic B-cell growth by combining antibody therapy with an anti-CD20 antibody or a antigen-binding fragment thereof, wherein said anti-CD40 antagonistic antibody or said antigen-binding fragment thereof are selected from the group consisting of: (a) an antibody or an antigen-binding fragment thereof that binds with an epitope capable of binding with the monoclonal antibody CHIR-5.9, which can be obtained from the hybridoma cell line deposited in the ATCC as Patent Deposit No. PTA-5542, or with the monoclonal antibody CHIR-12.12, which can be obtained from the line hybridoma cell deposited in the ATCC as Patent Deposit No. PTA-5543; (b) an antibody or an antigen binding fragment thereof that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID No. 10 or in SEQ ID No. 12; (c) an antibody or an antigen-binding fragment thereof that binds to an epitope comprising residues 82-89 of the human CD40 sequence shown in SEQ ID No. 10 or SEQ ID No. 12; and (d) an antibody or an antigen-binding fragment thereof that competes with the CHIR-5.9 monoclonal antibody, which can be obtained from the hybridoma cell line deposited in the ATCC as Patent Deposit No. PTA-5542 or the monoclonal antibody CHIR-12.12, which can be obtained from the hybridoma cell line deposited in the ATCC as Patent Deposit No. PTA-5543 in a competitive binding assay. |
| priorityDate | 2003-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1073.